NEW YORK (360Dx) – Australian proteomics firm Proteomics International (PILL) presented validation data at this week's American Diabetes Association annual meeting in San Diego that indicates its PromarkerD test could be helpful in identifying patients at risk of developing diabetic kidney disease.

In a prospective clinical study following 792 type 2 diabetes patients over four years, the company found that the test could identify patients who would develop kidney disease within that time period with a sensitivity of 86 percent and a specificity of 78 percent.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.